Mucoviscidose: enfin des traitements ciblés / Cystic fibrosis: targeted therapies, at last !

P. Burgel (Sorbonne Paris Cité, France)

Source: Virtual Congress 2020 – French programme 2020: Part I
Session: French programme 2020: Part I
Session type: Language session
Number: 4558
Disease area: -

WebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
P. Burgel (Sorbonne Paris Cité, France). Mucoviscidose: enfin des traitements ciblés / Cystic fibrosis: targeted therapies, at last !. Virtual Congress 2020 – French programme 2020: Part I

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Exacerbation aiguë de la fibrose pulmonaire idiopathique: ce qu'il ne faut plus faire et ce qu'il reste à faire. / Acute exacerbation of idiopathic pulmonary fibrosis: what should not be done and what remains to be done?
Source: Virtual Congress 2021 – French programme 2021
Year: 2021


Place des anti-IL5 dans les pathologies éosinophiliques (hors asthme sévère) / Anti-IL-5 therapy for indications other than severe asthma
Source: Virtual Congress 2020 – French programme 2020: Part II
Year: 2020


Exploration de la fonction respiratoire selon l'âge / Lung function testing and age
Source: Virtual Congress 2020 – French programme 2020: Part II
Year: 2020


Le roi est mort, vive le roi?
Source: Eur Respir J, 50 (1) 1701075; 10.1183/13993003.01075-2017
Year: 2017



Où en est-on dans la prise en charge de la Covid en septembre 2021 ? / Management of COVID-19: where are we ?
Source: Virtual Congress 2021 – French programme 2021
Year: 2021


Prise en charge de l’emphysème : Approche personnalisée / Management of emphysema: personalised approach
Source: Virtual Congress 2021 – French programme 2021
Year: 2021


Où en sommes-nous dans le dépistage du cancer bronchique? Screening for lung cancer: where are we?
Source: International Congress 2019 – French programme 2019: Part I
Year: 2019


Maladie thrombo-embolique: les nouvelles recommandations Thrombo-embolic disease: new recommendations
Source: International Congress 2019 – French programme 2019: Part I
Year: 2019


Syndrome obésité-hypoventilation: de la physiologie au traitementObesity hypoventilation: from pathophysiology to treatment
Source: International Congress 2016 – ERS/French Programme I
Year: 2016


Démarche de prise en charge des apnées centrales du sommeil Management of central sleep apnoea
Source: International Congress 2019 – French programme 2019: Part I
Year: 2019


Coaching et prise de décision partagée dans les maladies respiratoires chroniques Coaching and shared decision-making in chronic respiratory diseases
Source: International Congress 2019 – French programme 2019: Part II
Year: 2019


Tuberculose sous toutes ses formes Tuberculosis in all its forms
Source: International Congress 2019 – French programme 2019: Part II
Year: 2019


Nouvelles perspectives thérapeutiques dans la tuberculose multi-résistanteNew perspectives in the treatment of MDR-TB
Source: International Congress 2016 – ERS/French Programme II
Year: 2016


Réduction volumique par spirales dans le traitement de l’emphysème sévèreLung reduction coil treatment in severe emphysema
Source: International Congress 2016 – ERS/French Programme I
Year: 2016